$BLRX This is another study to compare BL-8040 to in SCM. Phil made a good point in the last earnings call about the market size being closer to $500 M annually. G-CSF is SOC in SCM and plerixafor is primarily being utilized as a rescue therapy. Populations are also aging and you’re seeing it in plerixafor’s #’s (chart looks like this 📈) ncbi.nlm.nih.gov/pmc/articl...
1
6
6 Likes